Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism

WANG Zhaotong; LU Ruitao; LIU Yonghong; WANG Hongsheng; ZENG Jun

doi:10.3971/j.issn.1000-8578.2016.12.003

Cancer Research on Prevention and Treatment > 2016 > 43(12): 1023-1029. > DOI: 10.3971/j.issn.1000-8578.2016.12.003

WANG Zhaotong, LU Ruitao, LIU Yonghong, WANG Hongsheng, ZENG Jun. Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2016, 43(12): 1023-1029. DOI: 10.3971/j.issn.1000-8578.2016.12.003

Citation:

PDF (5385 KB)

Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism

1.
Department of Medical Genetics & Cell Biology, School of Basic Sciences, Guangzhou Medical University, Guangzhou 511436, China
2.
Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

More Information

Corresponding author:
ZENG Jun, E-mail: 954506534@qq.com
Received Date: April 19, 2016
Revised Date: May 22, 2016
Available Online: February 04, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the effects of SAHA on the proliferation and apoptosis of human breast cancer cells MDA-MB-435 and related mechanisms.
Methods
After the treatment with different concentrations of SAHA, the proliferation, apoptosis, cell cycle arrest and protein expression of MDA-MB-435 cells were detected by MTT, FCM, Western blot and RT-PCR, respectively.
Results
MTT results showed that SAHA could inhibit cells proliferation in a dose-dependent manner, and FCM analysis showed that SAHA could induce ₂/M cell cycle arrest, downregulate mitochondria membrane potential, produce ROS and induce early apoptosis. Moreover, SAHA could downregulate cell cycle protein cyclin B, activate p38-MAPK and JNK, and inhibit P53 expression, and may not be via PI3K, P38 MAPK, ERK1/2, NF-κB or JNK pathways.
Conclusion
SAHA could inhibit the proliferation, induce cell cycle arrest and early apoptosis, and activate relative cell proliferation molecules in MDA-MB-435 cells, which suggesting that SAHA could be the drug candidate to breast cancer.
- SAHA,
- Breast cancer cells MDA-MB-435,
- Apotosis,
- MAPKs,
- p53

FullText(HTML)

References (40)

References

[1]	Bose S. Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes[J]. Adv Anat Pathol, 2015, 22(5): 306-13.
[1]	Bose S. Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes[J]. Adv Anat Pathol, 2015, 22(5): 306-13. doi: 10.1097/PAP.0000000000000084
[2]	Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-34. doi: 10.1158/1078-0432.CCR-06-3045
[2]	Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-34.
[3]	Wahba H A, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer[J]. Cancer Biol Med, 2015, 12(2): 106. http://cn.bing.com/academic/profile?id=37c09b2ec07eff80a5ae00660f1f7cc9&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Wahba H A, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer[J]. Cancer Biol Med, 2015, 12(2): 106.
[4]	Barbetti V, Gozzini A, Cheloni G, et al. Time-and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells[J]. Epigenetics, 2013, 8(2): 210-9. doi: 10.4161/epi.23538
[4]	Barbetti V, Gozzini A, Cheloni G, et al. Time-and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells[J]. Epigenetics, 2013, 8(2): 210-9.
[5]	Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J]. Nat Rev Cancer, 2006, 6(1): 38-51.
[5]	Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J]. Nat Rev Cancer, 2006, 6(1): 38-51. doi: 10.1038/nrc1779
[6]	Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents[J]. Annu Rev Pharmacol Toxicol, 2005, 45: 495-528. doi: 10.1146/annurev.pharmtox.45.120403.095825
[6]	Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents[J]. Annu Rev Pharmacol Toxicol, 2005, 45: 495-528.
[7]	Slingerland M, Guchelaar H J, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors[J]. Anti-Cancer Drug, 2014, 25(2): 140-9.
[7]	Slingerland M, Guchelaar H J, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors[J]. Anti-Cancer Drug, 2014, 25(2): 140-9. doi: 10.1097/CAD.0000000000000040
[8]	Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect[J]. Invest New Drug, 2010, 28(1): 3-20. http://cn.bing.com/academic/profile?id=e31c2f58a022d0a71baabb8545566997&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect[J]. Invest New Drug, 2010, 28(1): 3-20.
[9]	Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment[J]. Mol Med, 2000, 6(10): 849. http://cn.bing.com/academic/profile?id=bc602f90c251e7b085cdf4a884c7eba9&encoded=0&v=paper_preview&mkt=zh-cn
[9]	Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment[J].Mol Med, 2000, 6(10): 849.
[10]	Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy[J]. J Cell Biochem, 2009, 107(4): 600-8.
[10]	Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy[J]. J Cell Biochem, 2009, 107(4): 600-8. doi: 10.1002/jcb.v107:4
[11]	Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis[J]. Cell Death Differ, 2011, 18(12): 1904-13.
[11]	Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis[J]. Cell Death Differ, 2011, 18(12): 1904-13. doi: 10.1038/cdd.2011.71
[12]	Wang ZT, Chen ZJ, Jiang GM, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells[J].Cell Signal, 2016, 28(5): 506-15.
[12]	Wang ZT, Chen ZJ, Jiang GM, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells[J].Cell Signal, 2016, 28(5): 506-15. doi: 10.1016/j.cellsig.2016.02.006
[13]	Lee JS, Jeong SH, Soung YH, et al. SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells[J]. Chem-Biol Interact, 2009, 181(1): 61-70.
[13]	Lee JS, Jeong SH, Soung YH, et al. SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells[J]. Chem-Biol Interact, 2009, 181(1): 61-70. doi: 10.1016/j.cbi.2009.02.007
[14]	Kim BM, Chung HW. Hypoxia/reoxygenation induces apoptosis through a ROS-mediated caspase-8/Bid/Bax pathway in human lymphocytes[J]. Biochem Bioph Res Co, 2007, 363(3): 745-50. doi: 10.1016/j.bbrc.2007.09.024
[14]	Kim BM, Chung HW. Hypoxia/reoxygenation induces apoptosis through a ROS-mediated caspase-8/Bid/Bax pathway in human lymphocytes[J]. Biochem Bioph Res Co, 2007, 363(3): 745-50.
[15]	Arbab IA, Looi CY, Abdul AB, et al. Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, Survivin downregulation, caspase-9,-3/7 activation, and NF-κB inhibition[J]. Evid Based Complement Alternat Med, 2012, 2012: 856029.
[15]	Arbab IA, Looi CY, Abdul AB, et al. Dentatin induces apoptosis in prostate cancer cells via Bcl-2, Bcl-xL, Survivin downregulation, caspase-9,-3/7 activation, and NF-κB inhibition[J]. Evid Based Complement Alternat Med, 2012, 2012: 856029. http://cn.bing.com/academic/profile?id=cd57bcacad484223c98bf3898300b1e9&encoded=0&v=paper_preview&mkt=zh-cn
[16]	Hagenbuchner J, Ausserlechner MJ. Mitochondria and FOXO3: breath or die[J]. Front Physiol, 2013: 4,147. http://cn.bing.com/academic/profile?id=aa34574dfd08cc5d5164c61a3346711e&encoded=0&v=paper_preview&mkt=zh-cn
[16]	Hagenbuchner J, Ausserlechner MJ. Mitochondria and FOXO3: breath or die[J]. Front Physiol, 2013: 4,147.
[17]	Yu C, Subler M, Rahmani M, et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways[J]. Cancer Biol Ther, 2003, 2(5): 544-51. doi: 10.4161/cbt.2.5.454
[17]	Yu C, Subler M, Rahmani M, et al. Induction of apoptosis in BCR/ ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways[J]. Cancer Biol Ther, 2003, 2(5): 544-51.
[18]	Portanova P, Russo T, Pellerito O, et al. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells[J]. Int J Oncol, 2008, 33(2): 325-31. http://cn.bing.com/academic/profile?id=0a91807f322d106faacfe77128b35609&encoded=0&v=paper_preview&mkt=zh-cn
[18]	Portanova P, Russo T, Pellerito O, et al. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells[J]. Int J Oncol, 2008, 33(2): 325-31.
[19]	Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis[J]. Trends Mol Med, 2010, 16(11): 528-36. doi: 10.1016/j.molmed.2010.09.002
[19]	Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis[J]. Trends Mol Med, 2010, 16(11): 528-36.
[20]	Hui L, Zheng Y, Yan Y, et al. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D[J]. Oncogene, 2006, 25(55): 7305-10. doi: 10.1038/sj.onc.1209735
[20]	Hui L, Zheng Y, Yan Y, et al. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D[J]. Oncogene, 2006, 25(55): 7305-10.

Cited By

Get Citation

PDF

XML

Article views (1434) PDF downloads (698)

Turn off MathJax

Article Contents

Abstract

References

Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism

Abstract

References

Catalog

Download Center

Links

Contact Us

Effect of SAHA on Proliferation and Apoptosis of Breast Cancer Cells MDA-MB-435 and Related Mechanism

Abstract

References

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content